GLP-1 RAs are associated with increased odds of gastrointestinal adverse events including nausea, vomiting, and diarrhea with high to moderate quality evidence.
GLP-1 RAs show associations with lower odds of serious infections and incident respiratory disease, though evidence certainty varies.
Most noncardiometabolic outcomes, including fracture, dementia, thyroid disease, and cancer, have low or moderate certainty and exploratory findings.
Guideline-Based Recommendations
Diagnosis
Monitor for gastrointestinal adverse events in patients initiating GLP-1 RA therapy.
Management
Consider gastrointestinal side effect profiles when prescribing GLP-1 RAs.
Be cautious interpreting noncardiometabolic safety signals due to low evidence certainty.
Monitoring & Follow-up
Regularly assess for nausea, vomiting, and diarrhea during GLP-1 RA treatment.
Monitor for signs of serious infections and respiratory symptoms.
Risks
Increased risk of gastrointestinal adverse events (nausea, vomiting, diarrhea).
Potential but uncertain associations with thyroid disease and gastrointestinal diseases like GERD and gallbladder disease.
Exploratory and inconsistent findings regarding fracture risk, dementia, and cancer outcomes.
Patient & Prescribing Data
Over 3.6 million participants from 1,751 randomized clinical trials, primarily with type 2 diabetes or obesity
GLP-1 RAs increase gastrointestinal adverse events but may reduce serious infections; other safety signals remain uncertain and require cautious interpretation.
Clinical Best Practices
Inform patients about the likelihood of gastrointestinal side effects with GLP-1 RAs.
Use evidence-based monitoring protocols focusing on GI symptoms and infection signs.
Interpret non-GI safety signals with caution due to low to moderate evidence certainty and methodological limitations.
Consider individual patient risk factors when initiating GLP-1 RA therapy.
